Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma
- PMID: 38906162
- DOI: 10.1016/S2468-1253(24)00196-1
Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma
Conflict of interest statement
I have received grants or contracts, paid to my institution, from Servier, Exelixis, MSD, Basilea, Astellas, Zymeworks, Daiichi Sankyo, Genuity Science, and Roche. I have received consulting fees, paid to my institution, from Roche, AstraZeneca, and Servier.
Comment on
-
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.Lancet Gastroenterol Hepatol. 2024 Aug;9(8):705-717. doi: 10.1016/S2468-1253(24)00156-0. Epub 2024 Jun 18. Lancet Gastroenterol Hepatol. 2024. PMID: 38906161 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources
